文献速递儿科与产科急症

帕博利珠单抗治疗的晚期宫颈癌中贝伐珠单抗与铂类选择

Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical Cancer.
PubMed 文献 · JAMA Netw Open · 2026-07-01
一句话结论回顾性匹配队列显示,晚期宫颈癌一线帕博利珠单抗联合化疗时,顺铂与卡铂总生存相似;贝伐珠单抗与早期OS获益相关但随时间衰减,需前瞻性验证。

该比较效果研究基于TriNetX全球协作网回顾性多国队列,纳入2015年1月1日至2024年10月31日接受一线帕博利珠单抗+紫杉醇的晚期宫颈癌成人,排除既往癌症或贝伐珠单抗禁忌者,按年龄、种族 ethnicity、BMI、吸烟状态和既往放化疗进行倾向评分匹配。贝伐珠单抗组803例与未用组667例匹配出455对,12个月OS为74.8% vs 64.5%,24个月OS为56.2% vs 54.0%;瘘、肠穿孔、肺栓塞风险未见增加。结论需前瞻性验证。

要点

  • 贝伐珠单抗组12个月OS 74.8%(95%CI 70.4%-79.2%)高于未用组64.5%(95%CI 59.8%-69.2%),但24个月OS 56.2% vs 54.0%,早期获益随时间衰减。
  • 该研究为回顾性倾向评分匹配队列,结果需前瞻性验证,不能据此改变标准推荐。

适用人群与场景

  • 成人晚期宫颈癌(ICD-10-CM编码C53)患者,接受一线帕博利珠单抗+紫杉醇联合顺铂或卡铂,±贝伐珠单抗。
  • 排除既往癌症或贝伐珠单抗治疗禁忌者。
  • 场景为临床实践(TriNetX全球协作网多国回顾性队列),非急诊/ICU特定场景。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:回顾性多国比较效果队列,倾向评分匹配;数据来源TriNetX全球协作网;2015年1月1日至2024年10月31日。
  • 贝伐珠单抗 vs 未用比较:贝伐珠单抗组803例、未用组667例,匹配455对;12个月OS 74.8%(95%CI 70.4%-79.2%)vs 64.5%(95%CI 59.8%-69.2%);24个月OS 56.2%(95%CI 50.9%-61.5%)vs 54.0%(95%CI 48.7%-59.3%)。
  • 匹配变量:年龄、种族和 ethnicity、BMI、吸烟状态、既往放化疗。

证据类型、等级与局限

  • 证据类型:回顾性比较效果研究(倾向评分匹配队列),非RCT。
  • 局限:回顾性设计、依赖数据库编码、可能存在未测量混杂;原文结论明确需前瞻性验证。

对床旁实践的改变

  • 在晚期宫颈癌一线帕博利珠单抗+紫杉醇联合化疗时,顺铂与卡铂的选择可不因总生存差异而强制偏好某一种(基于本回顾性匹配结果,需前瞻验证)。
  • 贝伐珠单抗与早期OS获益相关但24个月时衰减,且未观察到瘘、肠穿孔、肺栓塞风险增加;是否使用仍需结合个体情况和前瞻证据。
  • 本研究非急诊/ICU场景,不改变抢救室或ICU的急性处置流程。

指南或共识出处

  • 原文未提及指南或共识名称;研究发表于JAMA Netw Open。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Pembrolizumab plus chemotherapy, with or without bevacizumab, improves overall survival (OS) in advanced cervical cancer (ACC), but platinum choice and bevacizumab use remain discretionary.

OBJECTIVE: To compare OS by platinum agent and bevacizumab use among patients with ACC receiving first-line pembrolizumab plus chemotherapy in a clinical setting.

DESIGN, SETTING, AND PARTICIPANTS: This comparative effectiveness study used a retrospective multinational cohort with propensity score matching in the TriNetX Global Collaborative Network. Participants included adults with ACC (International Statistical Classification of Diseases, 10th Revision, Clinical Modification, code C53) treated between January 1, 2015, and October 31, 2024. Patients with prior cancer or contraindications to bevacizumab therapy were excluded. Matching was performed on age, race and ethnicity, body mass index, smoking status, and prior chemoradiotherapy. Data were analyzed from November 19 to 28, 2024.

EXPOSURES: Cisplatin or carboplatin, with or without bevacizumab, both combined with first-line pembrolizumab plus paclitaxel.

MAIN OUTCOMES AND MEASURES: Two comparisons were analyzed: cisplatin vs carboplatin and bevacizumab vs no bevacizumab. The primary outcome was OS, defined as time from treatment initiation to death from any cause. Secondary outcomes were adverse events of special interest, including fistula, bowel perforation, and pulmonary embolism.

RESULTS: Among the 1931 patients receiving first-line pembrolizumab with paclitaxel (mean [SD] age, 54.0 [13.2] years), 623 matched pairs of cisplatin-treated patients (n = 719) and carboplatin-treated patients (n = 1212) were included. The mean (SD) age was 51.2 (12.7) years for cisplatin-treated patients and 50.8 (12.7) years for carboplatin-treated patients; the median follow-up was 10.8 (IQR, 3.7-18.0) months and 9.9 (IQR, 2.5-17.2) months, respectively. The median OS was 25.1 (IQR, 9.2 to not reached) months in both groups (HR, 0.98 [95% CI, 0.81-1.18]; P = .35). Bevacizumab-treated patients (n = 803) and those not receiving bevacizumab (n = 667) yielded 455 matched pairs. The mean (SD) age was 53.6 (13.3) years in the bevacizumab-treated group and 54.3 (13.3) years in the group not receiving bevacizumab; the median follow-up was 11.3 (IQR, 4.4-18.2) months and 8.4 (IQR, 1.6-15.1) months, respectively. Twelve-month OS was 74.8% (95% CI, 70.4%-79.2%) vs 64.5% (95% CI, 59.8%-69.2%), respectively; 24-month OS was 56.2% (95% CI, 50.9%-61.5%) vs 54.0% (95% CI, 48.7%-59.3%), respectively. No increased risk of fistula (odds ratio [OR], 0.94 [95% CI, 0.63-1.40]; P = .76), bowel perforation (OR, 1.21 [95% CI, 0.52-2.82]; P = .67), or pulmonary embolism (OR, 0.62 [95% CI, 0.38-1.01]; P = .052) was observed.

CONCLUSIONS AND RELEVANCE: In this comparative effectiveness study of patients with ACC in a clinical setting, cisplatin and carboplatin treatment were associated with similar effectiveness when combined with pembrolizumab. Bevacizumab was associated with early OS benefit, which attenuated over time. These findings warrant prospective validation.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Farolfi A, Casadei C, Scarpi E, et al. Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical Cancer. JAMA Netw Open. 2026. PMID: 42446878. doi:10.1001/jamanetworkopen.2026.23166

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。